Nanna L. Lausvig

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

Vlado Perkovic, Katherine R. Tuttle, Peter Rossing et al. · New England Journal of Medicine · 2024 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Ildiko Lingvay, Andrei‐Mircea Catarig, Juan P. Frías et al. · The Lancet Diabetes & Endocrinology · 2019 · 291 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

Rory J. McCrimmon, Andrei‐Mircea Catarig, Juan P. Frías et al. · Diabetologia · 2020 · 159 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials

Cyrus Desouza, Bertrand Cariou, Satish K. Garg et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 57 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Vanita R. Aroda, Matthew Capehorn, Louis Chaykin et al. · Diabetes Obesity and Metabolism · 2019 · 28 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17